+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID07492160

Evaluating Cabergoline to Prevent Lactation and Reduce Breast Symptoms After Abortion or Pregnancy Loss Between 12 and 18 Weeks

Led by Jefferson Drapkin · Updated on 2026-09-17

348

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate whether cabergoline can prevent lactation and reduce breast symptoms in pregnant individuals aged 18 years or older who undergo abortion or pregnancy loss between 12 and 18 weeks of gestation. The study focuses on how cabergoline affects the proportion of participants experiencing breast symptoms such as engorgement, milk leakage, tenderness, and the need for pain relief, compared with placebo. It also seeks to better understand the frequency and severity of these symptoms during the early second trimester. Participants are randomly assigned to receive either a single oral dose of cabergoline 1 mg or a placebo approximately one hour after their abortion or pregnancy loss procedure. Before the procedure, participants complete a baseline survey assessing breast symptoms. Follow-up surveys measuring symptom presence, severity, and bother occur on days 2, 3, 4, 7, and 14 after the procedure. A subset of about 20 participants may provide optional blood samples at selected times to measure serum prolactin levels, which help assess the biological impact of cabergoline. Throughout the study, participants complete multiple surveys using a validated breast symptoms inventory to evaluate engorgement, milk leakage, tenderness, and pain relief needs. Researchers primarily measure the proportion experiencing breast symptoms four days after the procedure, along with symptom severity, bother, and satisfaction. The study monitors participants for up to 14 days post-procedure, aiming to improve care and comfort for those experiencing abortion or pregnancy loss in the early second trimester.

CONDITIONS

Brief Title

Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms

Research Team

J

June Ng, MD

O

Olivia Sher, MPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here